Di Brizzi EV, Caccavale S, Di Caprio R, et al. Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?. Dermatol Pract Concept. 2024;14(4):e2024284. doi:10.5826/dpc.1404a284